Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapanisertib and Osimertinib in Advanced EGFR-Mutant NSCLC
NCT02503722Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2017
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of sapanisertib in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 28 days and Dose-Limiting Toxicity at 28 days. Started Mar 2017; status: active, not recruiting.
02
Drugs
sapanisertib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02503722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02503722.